Carvedilol (3.125mg)
Carvitop 3.125mg Tablet IR should be taken with food. You should take it in the dose and duration as advised by the doctor. It is important to take it even if you feel well or if your blood pressure is controlled. Do not stop this medicine without talking to the doctor as your condition could get worse.Making some changes in your lifestyle will help in improving your condition. These may include regular exercise, losing weight, smoking cessation, reducing alcohol intake, and reducing the amount of salt in your diet as advised by your doctor. This medicine is tolerated well by most patients but it may have a few side effects. These include dizziness, headache, breathlessness, and tiredness. Let your doctor know if these side effects bother you or do not go away.Before taking this medicine, let your doctor know if you have any heart or kidney diseases. Pregnant or breastfeeding mothers should also consult their doctor before taking this medicine.
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of Carvitop
10 tablet ir
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Carvitop 3.125mg Tablet IR is to be taken with food.
Carvitop 3.125mg Tablet IR is an alpha and beta blocker. It works by slowing down the heart rate and relaxing blood vessels which makes the heart more efficient at pumping blood around the body.
Related Warnings
It is unsafe to consume alcohol with Carvitop 3.125mg Tablet IR.
Carvitop 3.125mg Tablet IR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Carvitop 3.125mg Tablet IR is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Carvitop 3.125mg Tablet IR may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Carvitop 3.125mg Tablet IR is safe to use in patients with kidney disease. No dose adjustment of Carvitop 3.125mg Tablet IR is recommended.
However, inform your doctor if you have any underlying kidney disease. Regular monitoring of blood pressure is recommended for dose adjustment.
Carvitop 3.125mg Tablet IR should be used with caution in patients with liver disease. Dose adjustment of Carvitop 3.125mg Tablet IR may be needed. Please consult your doctor.
Use of Carvitop 3.125mg Tablet IR is not recommended in patients with severe liver disease.
Carvitop 3.125mg Tablet IR needs to be taken regularly as directed by your doctor. Suddenly stopping it may cause chest pain or heart attack. Your doctor may slowly lower your dose over a period of time before stopping it completely if required.
Yes, Carvitop 3.125mg Tablet IR may make you tired as well as dizzy. These may occur initially when you start the treatment or when the dose is increased. If you experience these symptoms you should not drive or operate machinery.
Yes, weight gain is a common side effect of Carvitop 3.125mg Tablet IR, but it does not occur in everyone. If you are taking Carvitop 3.125mg Tablet IR for heart failure, tell your doctor if you gain weight or have trouble breathing, as this may be a sign of fluid retention.
Use of Carvitop 3.125mg Tablet IR in patients with heart failure can rarely lead to deterioration of kidney function. However, Carvitop 3.125mg Tablet IR may cause risk of kidney failure in patients with low blood pressure (systolic blood pressure less than 100 mm Hg), patients with hardening of the arteries and/or having heart disease, or already have impaired kidney function. Such patients should be closely monitored during treatment with Carvitop 3.125mg Tablet IR. Although, kidney functions return to baseline when Carvitop 3.125mg Tablet IR is stopped.
Yes, a diabetic patient can take Carvitop 3.125mg Tablet IR, provided that there is a regular check on blood glucose levels. It has been noted that in well-controlled diabetes mellitus with mild to moderate hypertension, Carvitop 3.125mg Tablet IR did not have any effect on blood glucose levels. However, it is important to know that, using Carvitop 3.125mg Tablet IR class of medicines (beta-blockers) may hide the symptoms of hypoglycemia (decrease in glucose levels), especially an increase in heartbeat or palpitations. In addition to that, Carvitop 3.125mg Tablet IR may cause worsening of hyperglycemia (increase in blood glucose levels) in patients with heart failure and diabetes. Hence, it is recommended that blood glucose should be monitored while initiating, adjusting, or discontinuing the dose of Carvitop 3.125mg Tablet IR. Inform the doctor if there is any change in blood glucose levels during Carvitop 3.125mg Tablet IR therapy.
It is recommended that you take Carvitop 3.125mg Tablet IR with food, as food decreases the rate at which the medicine gets absorbed by the body. This will help to reduce the chances of orthostatic hypotension (low blood pressure which may cause dizziness or fainting when you stand up).
Carvitop 3.125mg Tablet IR may cause serious side effects such as fainting, shortness of breath, weight gain, swelling of the arms, hands, feet, ankles, or lower legs. Some may also experience chest pain, slow or irregular heartbeat, rash, hives, itching, and difficulty in breathing and swallowing. If you experience any of these symptoms call your doctor immediately.
If you take more than the recommended dose of Carvitop 3.125mg Tablet IR you may experience slow heartbeat, dizziness, fainting, difficulty breathing, vomiting, and loss of consciousness or seizures. Contact your doctor and seek immediate medical help in a nearby hospital.
Carvitop 3.125mg Tablet IR should be avoided if the patient has severe heart failure and is hospitalized in the intensive care unit or require certain intravenous medications that help support circulation (inotropic medications). In addition to that, Carvitop 3.125mg Tablet IR should be avoided in patients who are prone to asthma or other breathing problems, have a slow heartbeat or irregular heartbeat, have liver problems, and are allergic to Carvitop 3.125mg Tablet IR.
